Market revenue in 2023 | USD 203.8 million |
Market revenue in 2030 | USD 378.1 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | MDxHealth SA, Myriad Genetics Inc, Abbott Laboratories, Roche Holding AG, Bayer AG, Siemens Healthineers AG ADR, OPKO Health Inc, Exact Sciences Corp, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.85% in 2023. Horizon Databook has segmented the South Korea prostate cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
A study conducted in South Korea found that the risk of mortality associated to prostate cancer increases with the rising serum PSA concentration in men screened for the disease. The common guideline for biopsy state that results with PSA level < 1 ng/mL also increased the risk of death.
It was proven that low levels of PSA reflect a higher risk of prostate cancer. Thus, it fails to fulfill the goal of PSA screening to reduce the risk of uncertainty from prostate cancer; additionally, it increases unwanted biopsies. The study concluded that an increase in PSA screening can accelerate the risk of prostate cancer death in South Korean men.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea prostate cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into South Korea prostate cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account